Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[The latest data on posaconazole].

A Paugam1

  • 1Laboratoire de Parasitologie-Mycologie, hopital Cochin, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France. andre.paugam@cch.aphp.fr

Medecine Et Maladies Infectieuses
|February 3, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dermatophytic onychia: Effectiveness of rapid immunochromatographic diagnostic testing directly on samples compared to culture.

Annales de dermatologie et de venereologie·2021
Same author

Antifungal susceptibility testing practices in mycology laboratories in France, 2018.

Journal de mycologie medicale·2020
Same author

[Erratum to "Histoplasma capsulatum bone and joint infection" [Med. Mal. Infect. 47 (2017) 554-557]].

Medecine et maladies infectieuses·2017
Same author

[Histoplasma capsulatum bone and joint infection].

Medecine et maladies infectieuses·2017
Same author

[Lymphocytic meningitis in a 70-year-old woman].

La Revue de medecine interne·2016
Same author

Pulmonary aspergillosis.

Diagnostic and interventional imaging·2015
Same journal

[Etiology and clinical expression of angina].

Medecine et maladies infectieuses·2024
Same journal

[Rational use of antibiotics treatment in acute bronchitis].

Medecine et maladies infectieuses·2024
Same journal

Medecine et maladies infectieuses·2024
Same journal

[Detection of human rotaviruses in faeces : comparison of five methods].

Medecine et maladies infectieuses·2024
Same journal

Medecine et maladies infectieuses·2024
Same journal

Medecine et maladies infectieuses·2024
See all related articles

Posaconazole offers broad-spectrum antifungal activity, treating serious fungal infections in adults. It is also indicated for preventing invasive fungal infections in immunocompromised patients undergoing chemotherapy or stem cell transplants.

Area of Science:

  • Mycology
  • Pharmacology
  • Infectious Diseases

Context:

  • Posaconazole is a triazole antifungal agent with a broad spectrum of activity.
  • It is structurally similar to itraconazole.
  • Posaconazole is effective against yeasts, molds, and dimorphic fungi.

Purpose:

  • To provide an overview of posaconazole's spectrum of activity, indications, and clinical profile.
  • To highlight its use in refractory invasive fungal infections and prophylaxis in specific patient populations.

Summary:

  • Posaconazole is approved for treating invasive aspergillosis, fusariosis, mycetoma, chromoblastomycosis, and coccidioidomycosis in adults with refractory or intolerant conditions.
  • It is indicated for prophylaxis of invasive fungal infections in acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) patients with neutropenia and hematopoietic stem cell transplant (HSCT) recipients.

Related Experiment Videos

  • Its efficacy against zygomycetes and favorable tolerability with a lower drug interaction profile compared to other azoles are notable.

    • Impact:

    • Posaconazole expands treatment options for serious fungal infections, particularly in immunocompromised patients.
    • Its prophylactic use can reduce the incidence of invasive fungal infections in high-risk populations.
    • The drug offers a potentially safer alternative to existing azole antifungals due to its drug interaction profile.